Desmopressin vs Terlipressin
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Desmopressin or Terlipressin?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Desmopressin and Terlipressin?
Desmopressin selectively activates V2 receptors (antidiuretic, minimal vasopressor); terlipressin activates V1 receptors (vasopressor, splanchnic vasoconstriction) - receptor selectivity determines entirely different therapeutic applications.
Evidence Comparison
Desmopressin (DDAVP): FDA approved, decades of use for central diabetes insipidus, nocturnal enuresis, and von Willebrand disease. Terlipressin: FDA approved 2022 for hepatorenal syndrome type 1 (CONFIRM trial, Wong 2021, NEJM). Both have strong regulatory evidence for their respective indications.
Evidence Context Favoring Desmopressin
Central diabetes insipidus, nocturnal enuresis, or von Willebrand disease - V2-mediated antidiuretic applications.
Evidence Context Favoring Terlipressin
Hepatorenal syndrome or variceal bleeding - V1-mediated splanchnic vasoconstriction applications.
Side-by-Side Snapshot
| Evidence grade | Desmopressin: Level A Terlipressin: Level A |
|---|---|
| Research status | Desmopressin: FDA Approved Terlipressin: FDA Approved |
| Primary category | Desmopressin: Healing & Recovery Terlipressin: Healing & Recovery |
| Cited studies | Desmopressin: 3 Terlipressin: 3 |